SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Burcak Karaca, Mustafa Degirmenci, Ahmet Ozveren, Harika Atmaca, Emir Bozkurt, Bulent Karabulut, Ulus Ali Sanli, Ruchan Uslu, Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines, Cancer Chemotherapy and Pharmacology, 2015, 75, 6, 1273

    CrossRef

  2. 2
    Galina Khemlina, Sadakatsu Ikeda, Razelle Kurzrock, Molecular landscape of prostate cancer: Implications for current clinical trials, Cancer Treatment Reviews, 2015,

    CrossRef

  3. 3
    XianGuo Chen, HaiYan Cheng, TengFei Pan, Yi Liu, Yang Su, CuiPing Ren, DaKe Huang, XiaoJun Zha, ChaoZhao Liang, mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer, Molecular Carcinogenesis, 2015, 54, 8
  4. 4
    Guanxiong Ding, Jie Fang, Shijun Tong, Lianxi Qu, Haowen Jiang, Qiang Ding, Jun Liu, Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer, The Prostate, 2015, 75, 9
  5. 5
    Anton Neschadim, Alastair J.S. Summerlee, Joshua D. Silvertown, Targeting the relaxin hormonal pathway in prostate cancer, International Journal of Cancer, 2015, 137, 7
  6. 6
    Maria Katsogiannou, Hajer Ziouziou, Sara Karaki, Claudia Andrieu, Marie Henry de Villeneuve, Palma Rocchi, The hallmarks of castration-resistant prostate cancers, Cancer Treatment Reviews, 2015, 41, 7, 588

    CrossRef

  7. 7
    Hiroyuki Okudaira, Shuntaro Oka, Masahiro Ono, Takeo Nakanishi, David M. Schuster, Masato Kobayashi, Mark M. Goodman, Ikumi Tamai, Keiichi Kawai, Yoshifumi Shirakami, Accumulation of Trans-1-Amino-3-[18F]Fluorocyclobutanecarboxylic Acid in Prostate Cancer due to Androgen-Induced Expression of Amino Acid Transporters, Molecular Imaging and Biology, 2014, 16, 6, 756

    CrossRef

  8. 8
    Niels Eckstein, Bodo Haas, Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer, European Journal of Clinical Pharmacology, 2014, 70, 7, 791

    CrossRef

  9. 9
    Che-Kai Tsao, Matthew D. Galsky, William K. Oh, Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate Cancer, European Urology, 2014, 66, 2, 184

    CrossRef

  10. 10
    Pavel Sluka, Ian D. Davis, Cell mates: paracrine and stromal targets for prostate cancer therapy, Nature Reviews Urology, 2013, 10, 8, 441

    CrossRef

  11. 11
    Dajun Liu, Ying Liu, Limei Ran, Huiping Shang, Detian Li, GSTT1 and GSTM1 polymorphisms and prostate cancer risk in Asians: a systematic review and meta-analysis, Tumor Biology, 2013, 34, 5, 2539

    CrossRef

  12. 12
    Bai Xiang, Da-Wen Dong, Nian-Qiu Shi, Wei Gao, Zhen-Zhen Yang, Yi Cui, De-Ying Cao, Xian-Rong Qi, PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer, Biomaterials, 2013, 34, 28, 6976

    CrossRef

  13. 13
    Hui Zhu, Jorge A. Garcia, Targeting the Adrenal Gland in Castration-Resistant Prostate Cancer: A Case for Orteronel, a Selective CYP-17 17,20-Lyase Inhibitor, Current Oncology Reports, 2013, 15, 2, 105

    CrossRef